Center for Addiction Medicine

Past Studies

The work of the Center is carried out through clinical trials that investigate causes of substance use disorders and investigate novel treatments. These findings in these studies often affect the way treatment is delivered in actual healthcare environments. Information about the studies that are no longer being conducted may be accessed through the list below.

For more information on current research, visit the Active Studies page.

Marijuana Studies

The Effect of Cannabis on Cognition and Neuroimaging in those with Major Depressive Disorder [Details]

Principal Investigator(s): Gilman, 2017—2018
Study Reference: NIH/NIDA K01DA034093-04

The prevalence of use of MJ among those with Major Depressive Disorder (MDD) is unknown, but MDD is the third most common reason for individuals to seek medical MJ, after pain and insomnia. It is therefore of critical importance to understand the effects of MJ use and MDD on brain function, particularly in young adults. In this neuroimaging study, we investigated the neural correlates of emotion processing and neural activity in those with and without MDD and MJ use.

The Effect of Cannabis on Cognition and Neuroimaging in those with PTSD [Details]

Principal Investigator(s): Gilman, 2017—2018
Study Reference: NIH/NIDA K01DA034093-04

Post-traumatic stress disorder (PTSD) has the highest lifetime prevalence of all anxiety disorders (8-9%), shows high rates of comorbidity with MDD, and is a critical predictor of suicidality. Increasingly, PTSD patients are seeking alternative treatments to current interventions, many of which have not been proven to be effective and may in fact be harmful. The most pressing example of this is the increased prevalence of medical marijuana (MM) use among PTSD patients. While it is possible that MM use temporarily alleviates PTSD symptoms, such as stress responses, flashbacks and recurring traumatic memories/dreams, more data is needed to ensure that MM does not lead to negative outcomes, such as addiction or cognitive side effects. In this neuroimaging study, we investigated the neural correlates of emotion processing and neural activity in those with and without PTSD and MJ use.

Effect of Medical Marijuana on Neurocognition and Escalation of Use [Details]

Principal Investigator(s): Jodi Gilman , 2016—2020
Study Reference: 5K01DA034093

The purpose of this study is to evaluate the the effect of medical marijuana (MM) on a range of outcomes, including clinical symptoms, cognitive performance, brain function, and possible transition to cannabis use disorders (CUD), in adults who are interested in using medical marijuana to treat pain, insomnia, depression, or anxiety. We will conduct longitudal assessments over 6 months that will: (1) characterize the impact of MM on progression to CUD, as well as other indices of addiction such as increased tolerance and withdrawal among those who stop using MM, (2) assess, via daily dosing diaries, the effect of MM use patterns on use of other medications and perception of underlying disease symptomatology, (3) characterize the impact of MM on neurocognitive performance, including executive function, memory, attention, and decision-making and (4) examine evidence for impact of MM on brain function in the prefrontal cortex and reward regions.

Web-based Survey of Individuals Interested in Using Medical Marijuana [Details]

Principal Investigator(s): Gilman, 2015—2020
Study Reference: NIH/NIDA 1K01DA034093-01A

The aims of this study are to characterize the most common illnesses for which MM is sought, the reasons for seeking MM, reasons for hesitance to use and to characterize current marijuana use habits of those interested in using MM.

Cognition and Adolescent Health [Details]

Principal Investigator(s): Schuster, Gilman, Evins, 2015—2020
Study Reference: 5K01DA034093-03

The purpose of this study is to provide updated information on prevalence and frequency of cannabis use in relation to other forms of substance use in a representative sample of high-school aged adolescents, to evaluate the effect of contingency management on initial 30-day verified cannabis abstinence in adolescents and older adolescents who use cannabis at least weekly and are not seeking treatment, to determine whether there is cognitive dysfunction in cannabis use that persists in the short term (4 days) after use but resolves with extended abstinence (30 days) compared to cannabis users who do not quit and non-using controls and to estimate the rate of cognitive improvement with cannabis abstinence as a function of time since last use and concentration of detectable cannabis metabolites in urine.

Mentoring in Patient-Oriented Addiction Research [Details]

Principal Investigator(s): Kelly, 2014—2019
Study Reference: National Institute of Alcohol Abuse and Alcoholism/K24AA022136-01

This grant is designed to develop specific content expertise in treatment and recovery policy, and the design, implementation, and evaluation of treatment and recovery support service combinations. This grant also allows for mentoring junior investigators in patient-orientated addiction research (POAR).

Longitudinal Study of Neurocognitive Effects of Cannabis Use
Decision-Making and Drug Use [Details]

Principal Investigator(s): Gilman, 2013—2016
Study Reference: NIH/NIDA 1K01DA034093-01A1

The aim of the study is to design novel behavioral tasks that will allow us to separate and empirically measure factors that predict social influence. We would like to design new tasks based on classic psychological studies that will allows us to model social influence, to observe differences between non-dependent young adults aged 18-25 who use either alcohol (ALC) or marijuana (MJ), and age-matched controls (CON), in order to investigate differences in susceptibility to social influence and in neural activation of regions associated with social influence as a function of early drug use.

Internet ad for the Decision-Making and Drug Use Study

Using Imaging to Assess Effects of THC on Brain Activity [Details]

Principal Investigator(s): Gilman, 2013—2017
Study Reference: NIDA 1K01DA034093

The aim of this study is to assess the effects of THC intoxication using the medication dronabinol (synthetic THC) on resting state and task-based activation in the prefrontal cortex (PFC), as well as on neurocognitive task performance and correlations between these measurements and clinical signs of intoxication, as well as to investigate at which doses of dronabinol an effect on neurocognitive task performance or an effect on PFC activity can be observed.

Recovery Research Institute (RRI) [Details]

Principal Investigator(s): Kelly, 2011—2019
Study Reference: Tower Foundation and private donors

Some of the RRI projects include building and maintaining a website in order to provide a credible source of information to debunk addiction and recovery myths, and provide free access to the latest recovery research information; building and evaluating recovery support programs in the community; building and evaluating recovery support programs in educational settings such as high schools and colleges; understanding the impact of community mutual-help organizations; addiction treatment system program evaluation.

Mentoring in Addiction Treatment Research [Details]

Principal Investigator(s): Evins, 2010—2015
Study Reference: NIDA K24 DA030443

The major aim of this career award is to provide support for mentoring of research fellows and junior faculty and to support training for the PI in genetics and neuroimaging techniques that will enhance clinical trials of nicotine dependence treatment interventions.

Tobacco Studies

Concurrent PET D2/D3 Receptor Imaging and fMRI Cue Reactivity in Smokers [Details]

Principal Investigator(s): Evins, 2091—2015
Study Reference: NIDA R21 DA031925

This study aims to determine whether smokers have increased expression of dopamine D2/D3 receptors than do non-smokers and whether there is an association between D2/D3 expression, as measured with positron emission tomography, and functional MRI reactivity to smoking cues, which, when increased, predicts relapse to smoking after initial abstinence.

Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients (FITNESS) [Details]

Principal Investigator(s): Evins, 2014—2015
Study Reference: NIMH R01 MH104560

This project proposes to conduct an open-label, four-site randomized controlled trial of a fixed-dose, combination of drugs versus usual treatment for the prevention of cardiovascular disease among patients receiving second-generation antipsychotic drugs for severe mental illness. The trial assesses the effectiveness of an initial treatment strategy using moderate doses of HMG-Co A reductase inhibitors and angiotensin receptor blockers which have proven efficacy and safety. We will test this treatment strategy within mental health clinics.

Mentoring in Patient-Oriented Addiction Research [Details]

Principal Investigator(s): Kelly, 2014—2019
Study Reference: National Institute of Alcohol Abuse and Alcoholism/K24AA022136-01

This grant is designed to develop specific content expertise in treatment and recovery policy, and the design, implementation, and evaluation of treatment and recovery support service combinations. This grant also allows for mentoring junior investigators in patient-orientated addiction research (POAR).

A Positive Psychology Smartphone Intervention for Young Adult Intermittent Smokers [Details]

Principal Investigator(s): Hoeppner, B, 2014—2015
Study Reference: ECOR # 2014A051686

The goal of this project is to develop a positive psychology smoking cessation smartphone app for young adults who are intermittent smokers.

Trial of Integrated Smoking Cessation, Exercise and Weight Management in SMI [Details]

Principal Investigator(s): Daumit, Evins, 2014—2019
Study Reference: NIH/NIMH 5R01MH104553-04

This clinical trial tested the hypothesis that an 18-month CVD risk reduction program consisting of smoking cessation treatment and weight reduction and exercise would improve cardiovascular health in persons with serious mental illness.

Reduced Nicotine Cigarettes in Smokers with Mood and Anxiety Disorders [Details]

Principal Investigator(s): Evins, 2013—2018
Study Reference: P50 DA 036107-01

The aim of this study is to assess the effect of switching to gradually reduced nicotine content cigarettes on product use patterns and biomarkers of exposure, on psychiatric and nicotine withdrawal symptoms and on self-perception of tobacco dependence, self-report of intention to quit smoking, and actual smoking cessation attempts in smokers with mood and/or anxiety disorders.

Landing pages:
http://boston.craigslist.org/gbs/vol/5275723869.html
http://boston.craigslist.org/bmw/vol/5265708831.html

More information at ClinicalTrials.gov.

Smoking Cessation in College Student Smokers [Details]

Principal Investigator(s): Hoeppner, B.
Study Reference: K01 DA027097

This ecological momentary assessment (EMA) study (n=100) captured changes in smoking outcome expectancies and other thoughts and feeling in college student smokers in their natural environment as they were undergoing a quit attempt.

Ecological Momentary Assessment in Young Adult Intermittent Smokers [Details]

Principal Investigator(s): Hoeppner, B., 2013—2013
Study Reference: K01 DA027097

This pilot study tested the feasibility of non-daily young adult smokers using ecological momentary assessment while they were undergoing a quit attempt.

Impact of Electronic Cigarette Initiation on Motivation to Quit, Exposure to Smoke and Exposure to Nicotine [Details]

Principal Investigator(s): Hoeppner, B.
Study Reference: K01 DA027097

This pilot study tested the feasibility of daily smokers providing real-life real-time reports of their thoughts, feelings and smoking behavior while they were initiating and trying out electronic cigarette use.

Proof-of-Concept Trial of an Alpha-7 Nicotinic Agonist for Nicotine Dependence (Supplement) [Details]

Principal Investigator(s): Evins/Favaal, 2012—2015
Study Reference: Envivo Pharmaceuticals

This investigator-initiated study provides study medication and additional funding to supplement NIDA R01 DA030992 to evaluate the efficacy of a novel alpha-7 nicotinic cholinergic receptor partial agonist for reducing cognitive deficits associated with nicotine withdrawal and assess its efficacy as a smoking cessation treatment.

Assessment of Varenicline and Bupropion Hydrochloride for Smoking Cessation [Details]

Principal Investigator(s): Evins, 2011—2015
Study Reference: PFIZER. A3051123

A 24-week multinational, phase 4, randomized, double blind, active and placebo-controlled, multicenter study evaluating the neuropsychiatric safety and efficacy of 12 weeks varenicline tartrate 1 mg BID and bupropion hydrochloride 150 mg BID for smoking cessation in subjects with and without a history of psychiatric disorders. The objective this study is to characterize the neuropsychiatric safety profiles of varenicline and bupropion for subjects with and without a diagnosis of psychiatric disorder.

More information at ClinicalTrials.gov.

Follow up to Study A3051123: Cardiac Assessments after Smoking Cessation Treatments [Details]

Principal Investigator(s): Evins, 2011—2015
Study Reference: PFIZER. A3051123

This study is a non-treatment extension to study A3051123, aimed at collecting data on cardiovascular safety for all participants in the A3051123 trial for an additional 28 weeks, allowing for a total of 52 weeks of cardiovascular safety data collection.

More information at ClinicalTrials.gov.

Proof-of-Concept Trial of an Alpha-7 Nicotinic Agonist for Nicotine Dependence [Details]

Principal Investigator(s): Evins/Favaal, 2011—2015
Study Reference: NIDA R01 DA030992

The aim of this project is to conduct a Phase IIb, randomized clinical trial to evaluate the effect of an alpha-7 nicotinic cholinergic receptor partial agonist on cognitive deficits associated with nicotine withdrawal and assess its efficacy as a smoking cessation treatment when used as monotherapy or in conjunction with nicotine patch in a 2x2 design clinical trial.

More information at ClinicalTrials.gov.

Recovery Research Institute (RRI) [Details]

Principal Investigator(s): Kelly, 2011—2019
Study Reference: Tower Foundation and private donors

Some of the RRI projects include building and maintaining a website in order to provide a credible source of information to debunk addiction and recovery myths, and provide free access to the latest recovery research information; building and evaluating recovery support programs in the community; building and evaluating recovery support programs in educational settings such as high schools and colleges; understanding the impact of community mutual-help organizations; addiction treatment system program evaluation.

Enhancing Self-Control of Cigarette Craving with Real-Time fMRI [Details]

Principal Investigator(s): Evins, 2011—2014
Study Reference: NIDA R21 DA030523

The major aim of this project is to develop, optimize, and test real time functional magnetic resonance imaging neurofeedback from specified brain regions active during inhibitory control on learned control of brain activation while viewing smoking-related cues.

Mentoring in Addiction Treatment Research [Details]

Principal Investigator(s): Evins, 2010—2015
Study Reference: NIDA K24 DA030443

The major aim of this career award is to provide support for mentoring of research fellows and junior faculty and to support training for the PI in genetics and neuroimaging techniques that will enhance clinical trials of nicotine dependence treatment interventions.

Smoking Cessation and Cessation Maintenance in Smokers with and without Severe Mental Illness (SMI) During Sustained Pharmacotherapy with Varenicline [Details]

Principal Investigator(s): Evins, 2010—2015
Study Reference: NIDA K24 DA030443

This study is using a combined data set consisting of the data collected at MGH by Dr. Evins from a study population of smokers with SMI and a study with a comparable study design conducted at Pfizer in a population of smokers without SMI. The aim is to test the hypotheses that smokers without SMI will achieve a higher proportion of continuous tobacco abstinence during the maintenance of smoking cessation phase (i.e., in the 12 weeks post randomization, study weeks 12-24) than smokers with SMI, but this diagnosis effect will be normalized (i.e., will not be apparent) in the active pharmacotherapy (i.e., varenicline) group; smokers without SMI will have a longer mean time to relapse than smokers with SMI, and this difference will be greatest under placebo conditions and less pronounced in participants receiving active pharmacotherapy (varenicline) and that smokers without SMI will achieve a higher proportion of biochemically validated 7-day point prevalence tobacco abstinence during active, open-label treatment with varenicline than smokers with SMI, even after adjusting for baseline differences in age, gender, severity of nicotine dependence, cigarettes smoked per day, age of onset of daily smoking.

Effect of Mindfulness Training on Impulsivity in Smokers [Details]

Principal Investigator(s): Evins, 2010—2013
Study Reference: NIDA R03DA030899

Evaluation of feasibility and efficacy of Mindfulness Training (MT) in comparison to Cognitive Behavioral Therapy (CBT) for smoking cessation.

Cognitive Remediation with D-cycloserine to Improve Smoking Cessation Outcomes [Details]

Principal Investigator(s): Evins, 2010—2013
Study Reference: NIDA R21 DA030808

The major aim of this randomized clinical trial was to evaluate the effect of addition of the putative cognitive-enhancing agent, D-cycloserine, to cue exposure therapy on reactivity to smoking-related cues and relapse in recently abstinent smokers.

Extended Duration Varenicline for prevention of Relapse to Smoking in Patients with Schizophrenia [Details]

Principal Investigator(s): Evins, 2010—2014
Study Reference: Investigator Initiated Grant Pfizer Inc.

This investigator-initiated study provides study medication and additional funding to supplement NIDA R01 DA021245 ‘Smoking Cessation and Smoking Relapse Prevention in Patients with Schizophrenia’ to evaluate safety and efficacy of varenicline in smokers with schizophrenia.

Memory Reconsolidation Blockade as a Novel Intervention for Nicotine Dependence [Details]

Principal Investigator(s): Evins, 2008—2010
Study Reference: NIDA R21 DA025186

The major aim of this randomized clinical trial was to test the hypothesis that a single dose of propranolol given prior to smoking-related cue exposure would decrease psychophysiological responses to smoking cues one week later through a process of memory reconsolidation blockade.

Received Cutting Edge Basic Research Award.

Smoking Cessation and Smoking Relapse Prevention in Patients with Schizophrenia [Details]

Principal Investigator(s): Evins, 2007—2013
Study Reference: NIDA R01 DA021245

The major aim of this randomized treatment discontinuation trial was to test the hypothesis that smokers with schizophrenia require extended duration pharmacotherapy to prevent relapse to smoking.

Glycine Transport Inhibition for Nicotine Dependence in Schizophrenia [Details]

Principal Investigator(s): Evins, 2006—2012
Study Reference: NIDA R01 DA022276

The major aim of this randomized clinical trial was to test the hypothesis that a single dose of propranolol given prior to smoking-related cue exposure would decrease psychophysiological responses to smoking cues one week later through a process of memory reconsolidation blockade.

Cooperative Drug Discovery for the Treatment of Nicotine Dependence [Details]

Principal Investigator(s): Evins, Fava, 2004—2013
Study Reference: NIDA U01 DA019378

The major aim of this study was to test two novel Phase II compounds for efficacy for treatment of nicotine dependence and to test a predictive battery of putative biomarkers for response to treatment.

Alcohol and Mixed Drug Use Studies

Supplemental grant for Development and Testing of Adolescent Twelve-Step Facilitation [Details]

Principal Investigator(s): Kelly, 2014—2014
Study Reference: National Institute of Alcohol Abuse and Alcoholism/R01AA019664-01A1S1

This study is the first to develop and test in a randomized experimental design the efficacy of an integrated 12-step facilitation intervention tailored for young people.

Characterization and Evaluation of Addiction Recovery Community Centers [Details]

Principal Investigator(s): Kelly, 2014—2016
Study Reference: National Institute of Alcohol Abuse and Alcoholism /R21AA022693-01A1

This study will characterize and evaluate the public health and addiction recovery utility of addiction recovery community centers in the United States. This experimental/developmental investigation will characterize RCCs in New England and New York, and survey RCC clients to examine abstinence and remission rates and the accrual of recovery capital and enhanced quality of life.

Mentoring in Patient-Oriented Addiction Research [Details]

Principal Investigator(s): Kelly, 2014—2019
Study Reference: National Institute of Alcohol Abuse and Alcoholism/K24AA022136-01

This grant is designed to develop specific content expertise in treatment and recovery policy, and the design, implementation, and evaluation of treatment and recovery support service combinations. This grant also allows for mentoring junior investigators in patient-orientated addiction research (POAR).

Decision-Making and Drug Use [Details]

Principal Investigator(s): Gilman, 2013—2016
Study Reference: NIH/NIDA 1K01DA034093-01A1

The aim of the study is to design novel behavioral tasks that will allow us to separate and empirically measure factors that predict social influence. We would like to design new tasks based on classic psychological studies that will allows us to model social influence, to observe differences between non-dependent young adults aged 18-25 who use either alcohol (ALC) or marijuana (MJ), and age-matched controls (CON), in order to investigate differences in susceptibility to social influence and in neural activation of regions associated with social influence as a function of early drug use.

Internet ad for the Decision-Making and Drug Use Study

Development and Testing of Adolescent Twelve-Step Facilitation [Details]

Principal Investigator(s): Kelly, 2011—2016
Study Reference: National Institute of Alcohol Abuse and Alcoholism/R01AA019664-01A1

This study is the first to develop and test in a randomized experimental design the efficacy of an integrated 12-step facilitation intervention tailored for young people.

More information at ClinicalTrials.gov.

Enhanced Treatment for Binge Drinking Depressed College Students [Details]

Principal Investigator(s): Pedrelli, 2011—2016
Study Reference: K23 AA020064

This is the first randomized controlled study on the effectiveness of a treatment combining Cognitive Behavioral Therapy and Brief Motivational Intervention (CBT+BMI) for college students with depressive symptoms who binge drink. Given the severe consequences associated with binge drinking and depressive symptoms in college students identifying an effective treatment for this population has critical public health significance. The Treatment for Excessive Alcohol Use and Depression in Students (TREADS) study lasts approximately 12 weeks. As part of the study participants complete a baseline visits and then are randomized, by chance, like the flip of a coin, to one of two therapy programs. Both courses include eight therapy visits and teach coping skills for depressive symptoms. However, in one therapy program participants receive a personalized feedback about their alcohol use, while in the other program they may or may not talk about alcohol consumption depending on the students’ preference. Both courses teach the same coping skills for depressive symptoms but include different levels of focus on alcohol. Participants complete one follow-up assessment visit at the end of the therapy program and one four weeks later. The three assessment visits are reimbursed.

Landing page links:
https://www.massgeneral.org/psychiatry/forms/collegestress2.aspx
https://www.massgeneral.org/psychiatry/forms/collegestress.aspx

Recovery Research Institute (RRI) [Details]

Principal Investigator(s): Kelly, 2011—2019
Study Reference: Tower Foundation and private donors

Some of the RRI projects include building and maintaining a website in order to provide a credible source of information to debunk addiction and recovery myths, and provide free access to the latest recovery research information; building and evaluating recovery support programs in the community; building and evaluating recovery support programs in educational settings such as high schools and colleges; understanding the impact of community mutual-help organizations; addiction treatment system program evaluation.

Mechanisms and Moderators of Behavior Change among Youth Treated for Alcohol Use Disorders [Details]

Principal Investigator(s): Kelly, 2010—2013
Study Reference: National Institute of Alcohol Abuse and Alcoholism/R21AA018185-01

This study examined the treatment and continuing care responses of young adults (18-25yrs) with specific examination of the mechanisms through which relapse and recovery occurs, for whom, and what points.

Mentoring in Addiction Treatment Research [Details]

Principal Investigator(s): Evins, 2010—2015
Study Reference: NIDA K24 DA030443

The major aim of this career award is to provide support for mentoring of research fellows and junior faculty and to support training for the PI in genetics and neuroimaging techniques that will enhance clinical trials of nicotine dependence treatment interventions.

Adolescent Treatment and 12-Step Mutual-help Participation [Details]

Principal Investigator(s): Kelly, 2006—2010
Study Reference: National Institute of Alcohol Abuse and Alcoholism/R01AA015526-01

This study examined the process, proximal and distal treatment outcomes of this highly prevalent, but under-studied, treatment model among youth.

Depression and Other Mental Health Conditions

Integrated Behavioral Diabetes Management for Individuals with Serious Mental Illness [Details]

Principal Investigator(s): Cieslak, Evins, 2016—2018
Study Reference: Executive Committee on Community Health (ECOCH) Community Health/Health Equity Grant

The goal of this project was to improve health outcomes for people with serious mental illness (SMI) and diabetes, a highly prevalent comorbidity that results in high levels of healthcare utilization and poor medical outcomes, including significant premature mortality. We developed a 16-week tailored behavioral and educational group intervention for individuals with schizophrenia and diabetes, utilizing the concept of ‘reverse integrated care,’ bringing medical intervention into the community mental health setting. Core features of this intervention included motivational interviewing, basic education, and problem solving.

Enhancing Outcomes, Reducing Costs: Evaluating Peer Support for Mood Disorder [Details]

Principal Investigator(s): Kelly, 2014—2016
Study Reference: National Institute of Mental Health/R21MH101271-01

This study will characterize Depression and Bipolar Support Alliance (DBSA) participants and their participation in the organization; and, obtain preliminary estimates of the organizations’ purported clinical and recovery utility.

More information at ClinicalTrials.gov.

Neurobehavioral Predictors of Weight-Loss Surgery Outcomes [Details]

Principal Investigator(s): Evins, 2013—2015
Study Reference: Global Foundation for Eating Disorders

The major aim of this project is to begin to characterize neurobehavioral similarities and differences in certain phenotypes of obesity and addictive substance use disorders.

Decision-Making and Drug Use [Details]

Principal Investigator(s): Gilman, 2013—2016
Study Reference: NIH/NIDA 1K01DA034093-01A1

The aim of the study is to design novel behavioral tasks that will allow us to separate and empirically measure factors that predict social influence. We would like to design new tasks based on classic psychological studies that will allows us to model social influence, to observe differences between non-dependent young adults aged 18-25 who use either alcohol (ALC) or marijuana (MJ), and age-matched controls (CON), in order to investigate differences in susceptibility to social influence and in neural activation of regions associated with social influence as a function of early drug use.

Internet ad for the Decision-Making and Drug Use Study

Optimizing Real-time fMRI for Neurotherapeutic Discovery and Development [Details]

Principal Investigator(s): Evins, 2013—2014
Study Reference: Radcliff Institute for Advanced Study Conference Grant

This grant provided funding to hold an Exploratory Seminar at the Radcliffe Institute for Advanced Study to bring 18 scientists together from across the US for a two-day meeting with the aim of advancing development of real-time fMRI as a neurotherapeutic tool with applications to addictive disorders, obsessive-compulsive disorder, major depressive disorder, post-traumatic stress disorder, and optimized learning.

Reduced Nicotine Cigarettes in Smokers with Mood and Anxiety Disorders [Details]

Principal Investigator(s): Evins, 2013—2018
Study Reference: P50 DA 036107-01

The aim of this study is to assess the effect of switching to gradually reduced nicotine content cigarettes on product use patterns and biomarkers of exposure, on psychiatric and nicotine withdrawal symptoms and on self-perception of tobacco dependence, self-report of intention to quit smoking, and actual smoking cessation attempts in smokers with mood and/or anxiety disorders.

Landing pages:
http://boston.craigslist.org/gbs/vol/5275723869.html
http://boston.craigslist.org/bmw/vol/5265708831.html

More information at ClinicalTrials.gov.

Enhanced Treatment for Binge Drinking Depressed College Students [Details]

Principal Investigator(s): Pedrelli, 2011—2016
Study Reference: K23 AA020064

This is the first randomized controlled study on the effectiveness of a treatment combining Cognitive Behavioral Therapy and Brief Motivational Intervention (CBT+BMI) for college students with depressive symptoms who binge drink. Given the severe consequences associated with binge drinking and depressive symptoms in college students identifying an effective treatment for this population has critical public health significance. The Treatment for Excessive Alcohol Use and Depression in Students (TREADS) study lasts approximately 12 weeks. As part of the study participants complete a baseline visits and then are randomized, by chance, like the flip of a coin, to one of two therapy programs. Both courses include eight therapy visits and teach coping skills for depressive symptoms. However, in one therapy program participants receive a personalized feedback about their alcohol use, while in the other program they may or may not talk about alcohol consumption depending on the students’ preference. Both courses teach the same coping skills for depressive symptoms but include different levels of focus on alcohol. Participants complete one follow-up assessment visit at the end of the therapy program and one four weeks later. The three assessment visits are reimbursed.

Landing page links:
https://www.massgeneral.org/psychiatry/forms/collegestress2.aspx
https://www.massgeneral.org/psychiatry/forms/collegestress.aspx

Comprehensive CVD Risk Reduction Trial in Persons with Serious Mental Illness (Triumph Trial)
Smoking Cessation and Cessation Maintenance in Smokers with and without Severe Mental Illness (SMI) During Sustained Pharmacotherapy with Varenicline [Details]

Principal Investigator(s): Evins, 2010—2015
Study Reference: NIDA K24 DA030443

This study is using a combined data set consisting of the data collected at MGH by Dr. Evins from a study population of smokers with SMI and a study with a comparable study design conducted at Pfizer in a population of smokers without SMI. The aim is to test the hypotheses that smokers without SMI will achieve a higher proportion of continuous tobacco abstinence during the maintenance of smoking cessation phase (i.e., in the 12 weeks post randomization, study weeks 12-24) than smokers with SMI, but this diagnosis effect will be normalized (i.e., will not be apparent) in the active pharmacotherapy (i.e., varenicline) group; smokers without SMI will have a longer mean time to relapse than smokers with SMI, and this difference will be greatest under placebo conditions and less pronounced in participants receiving active pharmacotherapy (varenicline) and that smokers without SMI will achieve a higher proportion of biochemically validated 7-day point prevalence tobacco abstinence during active, open-label treatment with varenicline than smokers with SMI, even after adjusting for baseline differences in age, gender, severity of nicotine dependence, cigarettes smoked per day, age of onset of daily smoking.

Extended Duration Varenicline for prevention of Relapse to Smoking in Patients with Schizophrenia [Details]

Principal Investigator(s): Evins, 2010—2014
Study Reference: Investigator Initiated Grant Pfizer Inc.

This investigator-initiated study provides study medication and additional funding to supplement NIDA R01 DA021245 ‘Smoking Cessation and Smoking Relapse Prevention in Patients with Schizophrenia’ to evaluate safety and efficacy of varenicline in smokers with schizophrenia.

Smoking Cessation and Smoking Relapse Prevention in Patients with Schizophrenia [Details]

Principal Investigator(s): Evins, 2007—2013
Study Reference: NIDA R01 DA021245

The major aim of this randomized treatment discontinuation trial was to test the hypothesis that smokers with schizophrenia require extended duration pharmacotherapy to prevent relapse to smoking.

Glycine Transport Inhibition for Nicotine Dependence in Schizophrenia [Details]

Principal Investigator(s): Evins, 2006—2012
Study Reference: NIDA R01 DA022276

The major aim of this randomized clinical trial was to test the hypothesis that a single dose of propranolol given prior to smoking-related cue exposure would decrease psychophysiological responses to smoking cues one week later through a process of memory reconsolidation blockade.